Patient preferences in advanced or recurrent ovarian cancer

Laura J. Havrilesky, Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie Gaillard, Greg P. Samsa, David Cella, Kevin P. Weinfurt, Amy P. Abernethy, Shelby D. Reed

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The objective of this study was to elucidate relative preferences of women with ovarian cancer for symptoms, treatment-related side effects, and progression-free survival (PFS) relevant to choosing a treatment regimen.

METHODS: Women with advanced or recurrent ovarian cancer participated in a survey that included 3 methods to measure patient preferences (ratings, rankings, and a discrete-choice experiment) for 7 attributes: mode of administration, visit frequency, peripheral neuropathy, nausea and vomiting, fatigue, abdominal discomfort, and PFS. Participants were asked to choose between 2 unlabeled treatment scenarios that were characterized using the 7 attributes. Each participant completed 12 choice questions in which attribute levels were assigned according to an experimental design and a fixed-choice question representing 2 chemotherapy regimens for ovarian cancer.

RESULTS: In total, 95 women completed the survey. Participants' ratings and rankings revealed greater concern and importance for PFS than for any other attribute (P<.0001 for all). The discrete-choice experiment revealed that the relative odds that a participant would choose a scenario with 18 months, 21 months, and 24 months of PFS versus 15 months of PFS were 1.5 (P5.01), 3.4 (P<.001), and 7.5 (P<.001), respectively. However, participants' choices indicated that they were willing to accept a shorter PFS to avoid severe side effects: 6.7 months to reduce nausea and vomiting from severe to mild, 5.0 months to reduce neuropathy from severe to mild, and 3.7 months to reduce abdominal symptoms from severe to moderate.

CONCLUSIONS: PFS is the predominant driver of patient preferences for chemotherapy regimens. However, women in the current study were willing to trade significant PFS time for reductions in treatment-related toxicity.

Original languageEnglish (US)
Pages (from-to)3651-3659
Number of pages9
JournalCancer
Volume120
Issue number23
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Patient Preference
Ovarian Neoplasms
Disease-Free Survival
Nausea
Vomiting
Drug Therapy
Peripheral Nervous System Diseases
Therapeutics
Fatigue
Research Design
Odds Ratio

Keywords

  • Chemotherapy
  • Ovarian cancer
  • Patient preferences
  • Progression-free survival
  • Side effects

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Havrilesky, L. J., Secord, A. A., Ehrisman, J. A., Berchuck, A., Valea, F. A., Lee, P. S., ... Reed, S. D. (2014). Patient preferences in advanced or recurrent ovarian cancer. Cancer, 120(23), 3651-3659. https://doi.org/10.1002/cncr.28940

Patient preferences in advanced or recurrent ovarian cancer. / Havrilesky, Laura J.; Secord, Angeles Alvarez; Ehrisman, Jessie A.; Berchuck, Andrew; Valea, Fidel A.; Lee, Paula S.; Gaillard, Stephanie; Samsa, Greg P.; Cella, David; Weinfurt, Kevin P.; Abernethy, Amy P.; Reed, Shelby D.

In: Cancer, Vol. 120, No. 23, 01.01.2014, p. 3651-3659.

Research output: Contribution to journalArticle

Havrilesky, LJ, Secord, AA, Ehrisman, JA, Berchuck, A, Valea, FA, Lee, PS, Gaillard, S, Samsa, GP, Cella, D, Weinfurt, KP, Abernethy, AP & Reed, SD 2014, 'Patient preferences in advanced or recurrent ovarian cancer', Cancer, vol. 120, no. 23, pp. 3651-3659. https://doi.org/10.1002/cncr.28940
Havrilesky LJ, Secord AA, Ehrisman JA, Berchuck A, Valea FA, Lee PS et al. Patient preferences in advanced or recurrent ovarian cancer. Cancer. 2014 Jan 1;120(23):3651-3659. https://doi.org/10.1002/cncr.28940
Havrilesky, Laura J. ; Secord, Angeles Alvarez ; Ehrisman, Jessie A. ; Berchuck, Andrew ; Valea, Fidel A. ; Lee, Paula S. ; Gaillard, Stephanie ; Samsa, Greg P. ; Cella, David ; Weinfurt, Kevin P. ; Abernethy, Amy P. ; Reed, Shelby D. / Patient preferences in advanced or recurrent ovarian cancer. In: Cancer. 2014 ; Vol. 120, No. 23. pp. 3651-3659.
@article{9d7bbd7f5bd8473eb1650b39c6c0d434,
title = "Patient preferences in advanced or recurrent ovarian cancer",
abstract = "BACKGROUND: The objective of this study was to elucidate relative preferences of women with ovarian cancer for symptoms, treatment-related side effects, and progression-free survival (PFS) relevant to choosing a treatment regimen.METHODS: Women with advanced or recurrent ovarian cancer participated in a survey that included 3 methods to measure patient preferences (ratings, rankings, and a discrete-choice experiment) for 7 attributes: mode of administration, visit frequency, peripheral neuropathy, nausea and vomiting, fatigue, abdominal discomfort, and PFS. Participants were asked to choose between 2 unlabeled treatment scenarios that were characterized using the 7 attributes. Each participant completed 12 choice questions in which attribute levels were assigned according to an experimental design and a fixed-choice question representing 2 chemotherapy regimens for ovarian cancer.RESULTS: In total, 95 women completed the survey. Participants' ratings and rankings revealed greater concern and importance for PFS than for any other attribute (P<.0001 for all). The discrete-choice experiment revealed that the relative odds that a participant would choose a scenario with 18 months, 21 months, and 24 months of PFS versus 15 months of PFS were 1.5 (P5.01), 3.4 (P<.001), and 7.5 (P<.001), respectively. However, participants' choices indicated that they were willing to accept a shorter PFS to avoid severe side effects: 6.7 months to reduce nausea and vomiting from severe to mild, 5.0 months to reduce neuropathy from severe to mild, and 3.7 months to reduce abdominal symptoms from severe to moderate.CONCLUSIONS: PFS is the predominant driver of patient preferences for chemotherapy regimens. However, women in the current study were willing to trade significant PFS time for reductions in treatment-related toxicity.",
keywords = "Chemotherapy, Ovarian cancer, Patient preferences, Progression-free survival, Side effects",
author = "Havrilesky, {Laura J.} and Secord, {Angeles Alvarez} and Ehrisman, {Jessie A.} and Andrew Berchuck and Valea, {Fidel A.} and Lee, {Paula S.} and Stephanie Gaillard and Samsa, {Greg P.} and David Cella and Weinfurt, {Kevin P.} and Abernethy, {Amy P.} and Reed, {Shelby D.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/cncr.28940",
language = "English (US)",
volume = "120",
pages = "3651--3659",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "23",

}

TY - JOUR

T1 - Patient preferences in advanced or recurrent ovarian cancer

AU - Havrilesky, Laura J.

AU - Secord, Angeles Alvarez

AU - Ehrisman, Jessie A.

AU - Berchuck, Andrew

AU - Valea, Fidel A.

AU - Lee, Paula S.

AU - Gaillard, Stephanie

AU - Samsa, Greg P.

AU - Cella, David

AU - Weinfurt, Kevin P.

AU - Abernethy, Amy P.

AU - Reed, Shelby D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - BACKGROUND: The objective of this study was to elucidate relative preferences of women with ovarian cancer for symptoms, treatment-related side effects, and progression-free survival (PFS) relevant to choosing a treatment regimen.METHODS: Women with advanced or recurrent ovarian cancer participated in a survey that included 3 methods to measure patient preferences (ratings, rankings, and a discrete-choice experiment) for 7 attributes: mode of administration, visit frequency, peripheral neuropathy, nausea and vomiting, fatigue, abdominal discomfort, and PFS. Participants were asked to choose between 2 unlabeled treatment scenarios that were characterized using the 7 attributes. Each participant completed 12 choice questions in which attribute levels were assigned according to an experimental design and a fixed-choice question representing 2 chemotherapy regimens for ovarian cancer.RESULTS: In total, 95 women completed the survey. Participants' ratings and rankings revealed greater concern and importance for PFS than for any other attribute (P<.0001 for all). The discrete-choice experiment revealed that the relative odds that a participant would choose a scenario with 18 months, 21 months, and 24 months of PFS versus 15 months of PFS were 1.5 (P5.01), 3.4 (P<.001), and 7.5 (P<.001), respectively. However, participants' choices indicated that they were willing to accept a shorter PFS to avoid severe side effects: 6.7 months to reduce nausea and vomiting from severe to mild, 5.0 months to reduce neuropathy from severe to mild, and 3.7 months to reduce abdominal symptoms from severe to moderate.CONCLUSIONS: PFS is the predominant driver of patient preferences for chemotherapy regimens. However, women in the current study were willing to trade significant PFS time for reductions in treatment-related toxicity.

AB - BACKGROUND: The objective of this study was to elucidate relative preferences of women with ovarian cancer for symptoms, treatment-related side effects, and progression-free survival (PFS) relevant to choosing a treatment regimen.METHODS: Women with advanced or recurrent ovarian cancer participated in a survey that included 3 methods to measure patient preferences (ratings, rankings, and a discrete-choice experiment) for 7 attributes: mode of administration, visit frequency, peripheral neuropathy, nausea and vomiting, fatigue, abdominal discomfort, and PFS. Participants were asked to choose between 2 unlabeled treatment scenarios that were characterized using the 7 attributes. Each participant completed 12 choice questions in which attribute levels were assigned according to an experimental design and a fixed-choice question representing 2 chemotherapy regimens for ovarian cancer.RESULTS: In total, 95 women completed the survey. Participants' ratings and rankings revealed greater concern and importance for PFS than for any other attribute (P<.0001 for all). The discrete-choice experiment revealed that the relative odds that a participant would choose a scenario with 18 months, 21 months, and 24 months of PFS versus 15 months of PFS were 1.5 (P5.01), 3.4 (P<.001), and 7.5 (P<.001), respectively. However, participants' choices indicated that they were willing to accept a shorter PFS to avoid severe side effects: 6.7 months to reduce nausea and vomiting from severe to mild, 5.0 months to reduce neuropathy from severe to mild, and 3.7 months to reduce abdominal symptoms from severe to moderate.CONCLUSIONS: PFS is the predominant driver of patient preferences for chemotherapy regimens. However, women in the current study were willing to trade significant PFS time for reductions in treatment-related toxicity.

KW - Chemotherapy

KW - Ovarian cancer

KW - Patient preferences

KW - Progression-free survival

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84913616666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913616666&partnerID=8YFLogxK

U2 - 10.1002/cncr.28940

DO - 10.1002/cncr.28940

M3 - Article

C2 - 25091693

AN - SCOPUS:84913616666

VL - 120

SP - 3651

EP - 3659

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 23

ER -